Trials / Completed
CompletedNCT05093270
First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study of BGB-23339 in Healthy Participants
A First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 92 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the safety, tolerability, and pharmacokinetics of BGB-23339 and food effects in healthy participants
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGB-23339 | Administered orally as a tablet |
| DRUG | Placebo | Administered orally as a tablet |
Timeline
- Start date
- 2021-11-15
- Primary completion
- 2022-09-15
- Completion
- 2022-12-26
- First posted
- 2021-10-26
- Last updated
- 2025-09-22
Locations
3 sites across 2 countries: Australia, China
Source: ClinicalTrials.gov record NCT05093270. Inclusion in this directory is not an endorsement.